Your Complete Guide to Global Clinical Research and GCP Compliance
Digital Tools and Analytics to Forecast and Monitor M&A and Licensing Effects on Trials The landscape of clinical trials is continually evolving, particularly in the context of mergers and acquisitions (M&A) and licensing agreements that significantly impact how clinical research is conducted. For professionals engaged in clinical operations, regulatory affairs, and medical affairs, understanding the…
Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials The landscape of clinical research is rapidly evolving, influenced by technological advancements, novel regulatory frameworks, and innovative business models. As we delve into the future of clinical trials, it is vital that clinical operations, regulatory affairs, and medical affairs professionals…
Read More “Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials” »
Investor, Board and C-Suite Questions Around M&A and Licensing Effects on Trials—Answered In the highly dynamic landscape of clinical research, mergers and acquisitions (M&A), along with licensing agreements, can significantly impact the course of pharma clinical trials. Understanding their implications is essential for stakeholders across clinical operations, regulatory affairs, and medical affairs. This guide provides…
Vendor, Site and Partner Negotiation Tactics Driven by M&A and Licensing Effects on Trials Vendor, Site and Partner Negotiation Tactics Driven by M&A and Licensing Effects on Trials The global landscape of clinical trials is ever-changing, compelling clinical operations, regulatory affairs, and medical affairs professionals to develop robust negotiation tactics when dealing with vendors, sites,…
KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials In the evolving landscape of pharmaceutical clinical trials, understanding the impact of mergers and acquisitions (M&A) and licensing agreements is critical for stakeholders. This guide is designed to provide clinical operations,…
Read More “KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials” »
Scenario Planning: Best-Case and Worst-Case M&A and Licensing Effects on Trials Outlooks Scenario Planning: Best-Case and Worst-Case M&A and Licensing Effects on Trials Outlooks In the fast-evolving landscape of clinical research, mergers and acquisitions (M&A) and licensing agreements are pivotal in shaping the future of pharmaceutical development. These strategic decisions can substantially affect the trajectory…